Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds

Novartis, Amgen and Mallinckrodt relied on routine price hikes to meet their financial targets—and, to make sure they could keep increasing prices, they worked to inhibit competition and keep their monopoly pricing power, a congressional committee said Thursday as hearings continued on Capitol Hill.